Dear Editor,

An outbreak of unusual pneumonia in Wuhan, China recently was caused by infection of a novel type of corona-virus. The virus and disease were denoted as 2019-nCoV and COVID-19, respectively, by the World Health Organization (WHO). Most recently, 2019-nCoV was renamed SARS-CoV-2 by *Coronaviridae* Study Group (CSG) of the International Committee on Taxonomy of Viruses (ICTV) (Gorbalenya *et al.*[@CR3]), or HCoV-19, as a common name for the consistence with COVID-19, by a group of virologists in China (Jiang *et al.*[@CR5], [@CR6]). As of 7 March 2020, a total of 80,651 confirmed cases, including 3070 deaths, were reported in China (China CDC [@CR1]). Global spread is undeniable with serious implications for public health, thus calling for rapid development of effective therapeutics and prophylatics (Jiang *et al.*[@CR5], [@CR6]).

Very recently, it was found that horse anti-SARS-CoV and convalescent SARS patient sera had neutralizing effects against 2019-nCoV at a low dilution of 1:80 and 1:25, respectively (Zhou *et al.*[@CR10]; Hoffmann *et al.*[@CR4]). Although several SARS-CoV receptor-binding domain (RBD)-specific human monoclonal antibodies (mAbs), such as S230, m396 and 80R, exhibited no cross-reactivity with 2019-nCoV RBD (Wrapp *et al.*[@CR8]). CR3022, a SARS-CoV RBD-specific human mAb, was reported to bind with the RBD of spike (S) protein in 2019-nCoV with potential cross-neutralizing activity (Tian *et al.*[@CR7]). These studies suggest that the anti-SARS-CoV antibodies might be useful for the treatment of 2019-nCoV infection and people with history of SARS-CoV infection many years ago might be resistant to 2019-nCoV infection.

The S protein in coronavirus plays an essential role in virus entry, and it is also the main target of neutralizing antibodies (Du *et al.*[@CR2]). Sequence alignment indicated a 75.9% amino acid sequence identity between the S protein of SARS-CoV and that of 2019-nCoV (Supplementary Figure S1, Supplementary Table S1). SARS-related coronavirus (SARSr-CoV) WIV1 and Rs3367 have 92.3% amino acid sequence identity to SARS-CoV in S protein, while those between SARS-CoV and MERS-CoV is 28.7% (Supplementary Figure S1, Supplementary Table S1). It is worth noting that the RBDs of SARS-CoV and 2019-nCoV exhibited a significant difference, although they bind the same receptor (angiotensin-converting enzyme 2, ACE2) during virus infection (Zhou *et al.*[@CR10]). Therefore, despite sequence and receptor similarities, it is unclear whether the anti-SARS-CoV serum produced by immunization with S protein-based vaccine could cross-neutralize 2019-nCoV infection.

We previously developed SARS pseudovirus (SARS-PsV) and MERS pseudovirus (MERS-PsV), which were prepared by cotransfecting the plasmids of pNL4-3.luc.RE and pcDNA3.1-SARS, or MERS-CoV-S protein, to HEK293T cells (Fig. [1](#Fig1){ref-type="fig"}A) (Xia *et al.*[@CR9]). These pseudoviruses (PsVs) bear the S protein and a defective HIV-1 genome, including a luciferase reporter gene, and could simulate the virus to infect target cells, thus having native conformations (Fig. [1](#Fig1){ref-type="fig"}A) (Xia *et al.*[@CR9]). Consequently, we believed these PsVs to be potential immunogens to produce neutralizing antibodies. Female Balb/C mice (n = 5) were subcutaneously injected with SARS-PsV, MERS-PsV or PBS as a control using Freund's complete adjuvant for the prime immunization and vaccinated at 28 days after the first immunization using Freund's incomplete adjuvant for the boost immunization (Fig. [1](#Fig1){ref-type="fig"}B). Sera samples were collected from day 7 after the final vaccination.Fig. 1Neutralizing effects of sera from mice treated with SARS-PsV or MERS-PsV against SARS-PsV, MERS-PsV, 2019-nCoV-PsV, WIV1-PsV and Rs3367-PsV infection. **A** Schematic representation of the production of SARS-PsV and MERS-PsV. **B** The immunization procedure. **C** Detection of sera from SARS-PsV-, MERS-PsV- and PBS-treated mice for neutralization activity against SARS-PsV infection. **D** Assessment of sera from SARS-PsV-treated mice for neutralizing antibody titers against SARS-PsV infection. **E** Detection of sera from SARS-PsV-, MERS-PsV- and PBS-treated mice for neutralizing antibody titers against MERS-PsV infection. **F** Assessment of sera from MERS-PsV-treated mice for the neutralizing antibody titers against MERS-PsV infection. **G** Detection of sera from SARS-PsV-, MERS-PsV- and PBS-treated mice for neutralization activity against 2019-nCoV-PsV infection. **H**--**I** Detection of sera from SARS-PsV-, MERS-PsV- and PBS-treated mice for neutralization activity against WIV1-PsV and Rs3367-PsV, respectively. **J**--**K** Detection of sera from SARS-PsV-treated mice for neutralization activity against WIV1-PsV and Rs3367-PsV infection. **I** NT~50~ value of mouse sera agaisnt SARS-PsV, MERS-PsV, WIV1-PsV, Rs3367-PsV and 2019-nCoV-PsV infection. GraphPad Prism version 5.0 was used to perform all statistical analyses. ns, not significant; \**P *\< 0.05; \*\**P *\< 0.01; \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001.

We first tested day-35 sera for neutralization of SARS-PsV infection using ACE2-expressing 293T cells. As shown in Fig. [1](#Fig1){ref-type="fig"}C, compared with the PBS-treated group, significant neutralization (*P *\< 0.0001) was observed in the sera from SARS-PsV-treated mice at dilution of 1:100, 1:200, 1:400 and 1:800. The percent of inhibition of SARS-PsV infection in sera from the SARS-PsV-vaccinated group could reach \~ 97%, even at a dilution of 1:800. Then, the NT~50~s (50% neutralizing antibody titers) of these sera were further tested. As shown in Fig. [1](#Fig1){ref-type="fig"}D, the mean NT~50~ of the sera was 41,425. The sera from MERS-PsV-treated mice, as negative control, did not reach our NT~50~ threshold at a dilution of 1:100 and did not show a significant difference (*P* \> 0.5) compared with the PBS-treated control group. Then, we tested the neutralization effects of the sera against MERS-PsV infection using the Huh-7 cell line. We found significant MERS-PSV neutralization effects in the sera from MERS-PsV-treated mice (Fig. [1](#Fig1){ref-type="fig"}E). The NT~50~ of these sera was also detected as 5945 (Fig. [1](#Fig1){ref-type="fig"}F). However, the sera from SARS-PsV-treated mice could not significantly inhibit MERS-PsV infection, even at a dilution of 1:100 (Fig. [1](#Fig1){ref-type="fig"}E). In spite of the high neutralization titer in both groups, we did not observe a significant cross-neutralization effect.

To assess whether the SARS-PsV-treated mouse sera could show cross-neutralization effects for 2019-nCoV, we tested the inhibition effects of all sera using a 2019-nCoV pseudovirus system and Huh-7 cells as the target cell. No neutralization was detected, either for sera from SARS-PsV-treated mice or for MERS-PsV-treated mice, even at a dilution of 1: 100, compared with the sera from PBS-treated mice (Fig. [1](#Fig1){ref-type="fig"}G).

To investigate the ability to neutralize SARSr-CoVs, we further tested the inhibitory activities against two SARSr-CoVs, WIV1 and Rs3367. Interestingly, sera from SARS-treated mice could significantly neutralize WIVI-PsV and Rs3367-PsV with \~ 92% and \~ 87% inhibitory activities at a dilution of 1:800 (Fig. [1](#Fig1){ref-type="fig"}H and [1](#Fig1){ref-type="fig"}I). However, no neutralization was observed for MERS-PSV-treated mice sera, even at a dilution of 1:100, compared with the sera from PBS-treated control (Fig. [1](#Fig1){ref-type="fig"}H and [1](#Fig1){ref-type="fig"}I). Then, we further investigated whether the sera from SARS-CoV spike protein-treated mice could also cross-neutralize bat SARSr-CoV, WIV1-PsV and Rs3367-PsV with high titers. The NT~50~s for WIV1-PsV and Rs3367-PsV were 8787 and 7345, respectively (Fig. [1](#Fig1){ref-type="fig"}J and [1](#Fig1){ref-type="fig"}K), demonstrating that sera from mice treated with SARS-CoV S protein could potently cross-neutralize infection by SARS-CoV and SARSr-CoVs, but weakly for 2019-nCoV infection, although its S protein sequence is highly similar to that of SARS-CoV spike protein (Supplementary Figure S1, Supplementary Table S1).

Taken together, our results indicated that the sera of mice treated with pseudotyped SARS-CoV exhibited low titer of 2019-nCoV neutralization activity (\< 1:100), implying that it may not be practical to treat 2019-nCoV infection with anti-SARS-CoV antibodies and that people with history of SARS-CoV infection many years ago may not be resistant to 2019-nCoV infection. However, we cannot exclude the possibility that the low titer of the cross-neutralizing antibody is due to the low density of S protein on the surface of pseudovirus particles. Furthermore, modifying or reconstructing the SARS-CoV S protein may enhance the exposure of conformational neutralizing epitopes in RBD, in order to increase its immunogenicity for eliciting higher cross-neutralizing antibody responses against 2019-nCoV and emerging/reemerging coronaviruses in the future.
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